We investigated the role of the transcriptional regulator Id2 in the context of MLL-rearranged acute myeloid leukemia (AML). Using an Id2/GFP-reporter mouse model of MLL-AF9-driven AML, we showed that Id2 is expressed heterogeneously across the leukemic population. Moreover, differential expression of Id2 and the stemness marker Kit defines subsets of AML cells with different leukemogenic properties with lower levels of Id2 associated with enrichment in leukemia stem cell potential. To define gene expression patterns associated with distinct endogenous levels of Id2 and higher LSC potential, RNA sequencing analysis was performed on FACS-sorted KitHIId2HI (BM_Kplus-Iplus), KitHIId2LOW(BM_Kplus-Iminus), KitLOWId2HI (BM_Kminus-Iplus) and KitLOWId2LOW (BM_Kminus-Iminus) MLL-AF9-cherry+ AML cells obtained from bone marrow of terminally sick mice. SOURCE: Margherita Ghisi (margherita.ghisi@gmail.com) - Gene Regulation Peter MacCallum Cancer Centre

Pluto Bioinformatics

GSE68461: RNA sequencing analysis of murine MLL-AF9 acute myeloid leukemia cells expressing different levels of Id2 and Kit